MA54327A - KRAS G12C INHIBITORS - Google Patents
KRAS G12C INHIBITORSInfo
- Publication number
- MA54327A MA54327A MA054327A MA54327A MA54327A MA 54327 A MA54327 A MA 54327A MA 054327 A MA054327 A MA 054327A MA 54327 A MA54327 A MA 54327A MA 54327 A MA54327 A MA 54327A
- Authority
- MA
- Morocco
- Prior art keywords
- kras
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102200006538 rs121913530 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946586P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/063272 WO2021118877A1 (en) | 2019-12-11 | 2020-12-04 | Kras g12c inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54327A true MA54327A (en) | 2022-04-13 |
| MA54327B1 MA54327B1 (en) | 2022-12-30 |
Family
ID=74106135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54327A MA54327B1 (en) | 2019-12-11 | 2020-12-04 | Kras g12c inhibitors |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11731984B2 (en) |
| EP (1) | EP3886991B1 (en) |
| JP (1) | JP7023421B2 (en) |
| KR (1) | KR102546592B1 (en) |
| CN (2) | CN117820333A (en) |
| AR (1) | AR120700A1 (en) |
| AU (2) | AU2020402701B2 (en) |
| CA (1) | CA3161162A1 (en) |
| CL (1) | CL2022001513A1 (en) |
| CO (1) | CO2022008091A2 (en) |
| CR (1) | CR20220258A (en) |
| DK (1) | DK3886991T3 (en) |
| DO (1) | DOP2022000117A (en) |
| EC (1) | ECSP22046699A (en) |
| ES (1) | ES2929700T3 (en) |
| HR (1) | HRP20221301T1 (en) |
| HU (1) | HUE060684T2 (en) |
| IL (2) | IL304534B1 (en) |
| JO (2) | JOP20220142B1 (en) |
| LT (1) | LT3886991T (en) |
| MA (1) | MA54327B1 (en) |
| MD (1) | MD3886991T2 (en) |
| MX (2) | MX2022006986A (en) |
| PE (1) | PE20230238A1 (en) |
| PH (1) | PH12022551424A1 (en) |
| PL (1) | PL3886991T3 (en) |
| PT (1) | PT3886991T (en) |
| RS (1) | RS63719B1 (en) |
| SA (1) | SA522432955B1 (en) |
| SI (1) | SI3886991T1 (en) |
| TW (1) | TWI765448B (en) |
| UA (1) | UA128806C2 (en) |
| WO (1) | WO2021118877A1 (en) |
| ZA (1) | ZA202205218B (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020085504A1 (en) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | Method for producing chloroazole carboxylate derivative using sandmeyer reaction with light irradiation |
| CN114867726B (en) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Small molecule inhibitors of KRAS G12C mutants |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| TWI799871B (en) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | Tricyclic compound, its preparation method and medical application |
| WO2021245055A1 (en) | 2020-06-02 | 2021-12-09 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN116368130A (en) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | Heterocyclic compounds and their uses |
| MX2023002248A (en) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations. |
| AU2021347232A1 (en) | 2020-09-23 | 2023-04-27 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114437107B (en) * | 2020-11-06 | 2025-04-04 | 江苏先声药业有限公司 | Piperazine compounds and their applications |
| TWI880049B (en) * | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20240293558A1 (en) | 2021-06-16 | 2024-09-05 | Erasca, Inc. | Kras inhibitor conjugates |
| CN117677398A (en) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | Medicines for the treatment and/or prevention of cancer |
| WO2023066371A1 (en) | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| US20250129096A1 (en) * | 2021-12-01 | 2025-04-24 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20250313553A1 (en) * | 2021-12-01 | 2025-10-09 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20250145608A1 (en) * | 2021-12-01 | 2025-05-08 | Boehringer Ingelheim Int'l GmbH Corp. | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118647620A (en) * | 2021-12-01 | 2024-09-13 | 勃林格殷格翰国际有限公司 | Cyclic 2-amino-3-cyanothiophene and its derivatives for cancer treatment |
| US20250059187A1 (en) | 2021-12-22 | 2025-02-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| CN118434422A (en) | 2021-12-28 | 2024-08-02 | 阿斯利康(英国)有限公司 | Combination of antibody-drug conjugates and RASG12C inhibitors |
| EP4486345A1 (en) * | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| KR20240163107A (en) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | Heterocyclic compounds and their uses |
| JP7676677B2 (en) | 2022-03-25 | 2025-05-14 | イーライ リリー アンド カンパニー | KRAS inhibitors |
| JP2025511697A (en) * | 2022-04-07 | 2025-04-16 | イーライ リリー アンド カンパニー | Methods for Making KRAS G12C Inhibitors |
| CA3247183A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
| WO2023246903A1 (en) * | 2022-06-24 | 2023-12-28 | 暨南大学 | Selenium-containing heterocyclic compound, pharmaceutical composition thereof and use thereof |
| EP4547251A1 (en) * | 2022-06-30 | 2025-05-07 | Eli Lilly and Company | Kras g12c inhibitor for treating cancer |
| KR20250042155A (en) | 2022-07-27 | 2025-03-26 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Condensed ring compound, method for preparing the same and medical application thereof |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| AU2023349002A1 (en) | 2022-09-30 | 2025-05-15 | Trasveda Ltd. | Compounds with anti-kras mutant tumor activity |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2024206747A1 (en) | 2023-03-30 | 2024-10-03 | Eli Lilly And Company | Kras inhibitors |
| EP4688792A1 (en) | 2023-03-31 | 2026-02-11 | Eli Lilly and Company | Kras inhibitors |
| EP4700027A1 (en) | 2023-04-21 | 2026-02-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of nitrogen-containing tetracyclic compound and preparation method therefor |
| CN120981456A (en) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | Heterocyclic compounds and their uses |
| WO2024248123A1 (en) | 2023-06-02 | 2024-12-05 | 第一三共株式会社 | Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor |
| CN121605110A (en) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | Substituted heterocyclic compounds and uses thereof |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (en) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | Spirocyclic dihydropyranopyridine kras inhibitors |
| WO2025072457A1 (en) | 2023-09-27 | 2025-04-03 | Eli Lilly And Company | Kras inhibitors |
| TW202529768A (en) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | Therapies for the treatment of cancer |
| AU2024358622A1 (en) | 2023-10-11 | 2026-04-16 | Eli Lilly And Company | Process for making a kras g12c inhibitor |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026059955A1 (en) | 2024-09-11 | 2026-03-19 | Eli Lilly And Company | (3-((6-(2-amino-benzo[d]thiazol-4-yl)-3-(pyrrolidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)amino)- piperidin-2-one derivatives as kras inhibitors for the treatment of cancer |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| US12600733B2 (en) | 2024-10-01 | 2026-04-14 | Eli Lilly And Company | KRAS inhibitors |
| WO2026075942A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090318412A1 (en) * | 2006-07-11 | 2009-12-24 | Takahiro Matsumoto | Tricyclic heterocyclic compound and use thereof |
| AU2014331794C1 (en) * | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| TWI659021B (en) * | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Inhibitors of kras g12c |
| JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| JP2018513853A (en) * | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | Substituted quinazoline compounds and methods of use thereof |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| MA50077A (en) * | 2017-09-08 | 2020-07-15 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| HRP20230377T1 (en) * | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW202012415A (en) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | Chemical compounds |
| TW202033518A (en) | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c inhibitors |
| ES3010507T3 (en) * | 2019-03-05 | 2025-04-03 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| CN112390818B (en) | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | Substituted heteroaromatic ring dihydropyrimidinone derivatives, its preparation method and medical application |
-
2020
- 2020-12-04 ES ES20834024T patent/ES2929700T3/en active Active
- 2020-12-04 CN CN202311816497.XA patent/CN117820333A/en active Pending
- 2020-12-04 HR HRP20221301TT patent/HRP20221301T1/en unknown
- 2020-12-04 DK DK20834024.0T patent/DK3886991T3/en active
- 2020-12-04 UA UAA202201784A patent/UA128806C2/en unknown
- 2020-12-04 WO PCT/US2020/063272 patent/WO2021118877A1/en not_active Ceased
- 2020-12-04 IL IL304534A patent/IL304534B1/en unknown
- 2020-12-04 KR KR1020227019240A patent/KR102546592B1/en active Active
- 2020-12-04 TW TW109142894A patent/TWI765448B/en active
- 2020-12-04 PT PT208340240T patent/PT3886991T/en unknown
- 2020-12-04 RS RS20220956A patent/RS63719B1/en unknown
- 2020-12-04 MA MA54327A patent/MA54327B1/en unknown
- 2020-12-04 AU AU2020402701A patent/AU2020402701B2/en active Active
- 2020-12-04 HU HUE20834024A patent/HUE060684T2/en unknown
- 2020-12-04 IL IL293394A patent/IL293394B2/en unknown
- 2020-12-04 PH PH1/2022/551424A patent/PH12022551424A1/en unknown
- 2020-12-04 PE PE2022001047A patent/PE20230238A1/en unknown
- 2020-12-04 MX MX2022006986A patent/MX2022006986A/en unknown
- 2020-12-04 SI SI202030102T patent/SI3886991T1/en unknown
- 2020-12-04 US US17/111,676 patent/US11731984B2/en active Active
- 2020-12-04 PL PL20834024.0T patent/PL3886991T3/en unknown
- 2020-12-04 MD MDE20210978T patent/MD3886991T2/en unknown
- 2020-12-04 CR CR20220258A patent/CR20220258A/en unknown
- 2020-12-04 CN CN202080085553.5A patent/CN114828964B/en active Active
- 2020-12-04 JP JP2021539866A patent/JP7023421B2/en active Active
- 2020-12-04 LT LTEPPCT/US2020/063272T patent/LT3886991T/en unknown
- 2020-12-04 CA CA3161162A patent/CA3161162A1/en active Pending
- 2020-12-04 EP EP20834024.0A patent/EP3886991B1/en active Active
- 2020-12-09 AR ARP200103420A patent/AR120700A1/en unknown
-
2022
- 2022-05-11 ZA ZA2022/05218A patent/ZA202205218B/en unknown
- 2022-06-07 DO DO2022000117A patent/DOP2022000117A/en unknown
- 2022-06-07 CO CONC2022/0008091A patent/CO2022008091A2/en unknown
- 2022-06-08 MX MX2025002170A patent/MX2025002170A/en unknown
- 2022-06-08 CL CL2022001513A patent/CL2022001513A1/en unknown
- 2022-06-09 JO JOJO/P/2022/0142A patent/JOP20220142B1/en active
- 2022-06-10 EC ECSENADI202246699A patent/ECSP22046699A/en unknown
- 2022-06-12 SA SA522432955A patent/SA522432955B1/en unknown
-
2023
- 2023-06-28 US US18/343,326 patent/US20230339968A1/en active Pending
-
2024
- 2024-04-18 AU AU2024202573A patent/AU2024202573B2/en active Active
- 2024-09-30 JO JOJO/P/2024/0216A patent/JOP20240216A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54327A (en) | KRAS G12C INHIBITORS | |
| EP4087573A4 (en) | KRAS G12C INHIBITORS | |
| IL290845A (en) | kras g12d inhibitors | |
| EP3844151A4 (en) | KRAS G12C INHIBITORS | |
| FR24C1026I2 (en) | KRAS G12C INHIBITORS | |
| EP3790551A4 (en) | KRAS G12C INHIBITORS | |
| EP4322945A4 (en) | KRAS G12C INHIBITORS | |
| EP4192585A4 (en) | KRAS G12D INHIBITORS | |
| EP4182313A4 (en) | KRAS G12D INHIBITORS | |
| EP4240489A4 (en) | KRAS G12D INHIBITORS | |
| EP4007752C0 (en) | KIF18A INHIBITORS | |
| DK3999506T3 (en) | PARP1 INHIBITORS | |
| EP4007753C0 (en) | KIF18A INHIBITORS | |
| EP4007756C0 (en) | KIF18A inhibitors | |
| EP3458445A4 (en) | INHIBITORS OF KRAS G12C | |
| EP3801503A4 (en) | SARM1 INHIBITORS | |
| EP3761992A4 (en) | ARGINASE INHIBITORS | |
| EP3980011C0 (en) | SARM1 INHIBITORS | |
| EP3938358A4 (en) | RAD51 INHIBITORS | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| EP3801499A4 (en) | MRSA1 INHIBITORS | |
| EP3976797A4 (en) | ANTI-CRISPR INHIBITORS | |
| HK40055500A (en) | Kras g12c inhibitors |